Effects of treatment regimens on survival in patients with malignant pleural mesothelioma

Basit Öğe Kaydı
dc.contributor.authorAbakay, A.
dc.contributor.authorAbakay, O.
dc.contributor.authorTanrikulu, A. C.
dc.contributor.authorSezgi, C.
dc.contributor.authorSen, H.
dc.contributor.authorKaya, H.
dc.contributor.authorKucukoner, M.
dc.date.accessioned2024-04-24T17:44:55Z
dc.date.available2024-04-24T17:44:55Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractBACKGROUND AND OBJECTIVE: In this study, we aimed to investigate the factors affecting the survival of patients with malignant pleural mesothelioma (MPM) according to their treatment regimens, including best supportive care (BSC), chemotherapy, surgical group and multimodality (MM) therapy. PATIENTS: A retrospective analysis was performed on clinical data and treatment outcomes of 400 patients registered in our hospital with MPM between January 1989 and April 2010. RESULTS: Mean age (p < 0.001), presence of asbestos exposure (p = 0.0014), presence of smoking history (p < 0.001), Karnofsky performance status (p < 0.001), histological subtype (p = 0.034) and stage (p < 0.001) variables were found to be significantly different among the four treatment regimens. Mean survival time of all patients was 12.32 months. Mean survival time 10.5 months for the BSC group, 15.7 for the surgical group, 16.02 for the chemotherapy group, and 26.55 for the MM group. There were significant differences in mean survival time among the four treatment regimens. In addition, a significant difference was found in survival time between the two chemotherapy groups (p = 0.032). Mean survival time for cisplatin + gemcitabine was found to be 14.49 months and for cisplatin + pemetrexed, 18.34 months. CONCLUSIONS: The MM group had better survival rates than the other groups. The new chemotherapy combination, cisplatin + pemetrexed, can be helpful in improving survival time.en_US
dc.identifier.endpage24en_US
dc.identifier.issn1128-3602
dc.identifier.issue1en_US
dc.identifier.pmid23329519
dc.identifier.startpage19en_US
dc.identifier.urihttps://hdl.handle.net/11468/22345
dc.identifier.volume17en_US
dc.identifier.wosWOS:000319223400003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMesotheliomaen_US
dc.subjectSurvivalen_US
dc.subjectTreatmenten_US
dc.subjectPrognosisen_US
dc.titleEffects of treatment regimens on survival in patients with malignant pleural mesotheliomaen_US
dc.titleEffects of treatment regimens on survival in patients with malignant pleural mesothelioma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu